Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Theralase Technologies ( (TSE:TLT) ) just unveiled an update.
Theralase Technologies has identified an additional mechanism by which its lead compound Ruvidar inactivates herpes simplex virus type 1, adding to earlier data showing the drug outperforms standard therapy Acyclovir in preclinical testing. The company’s researchers demonstrated that positively charged Ruvidar binds to negatively charged HSV-1, neutralizing the virus’s surface charge, preventing cell entry and proliferation, and achieving up to an eight-log, or 99.999999%, reduction in viral load in vitro.
Executives say the findings confirm Ruvidar’s ability to attack viruses on multiple fronts, from disrupting the viral life cycle inside cells to blocking viral entry and potentially interfering with genome replication. The expanded understanding of Ruvidar’s antiviral mechanisms is expected to support its clinical development as a broad-spectrum antiviral therapy, with potential implications for the large global population affected by viral infections.
The most recent analyst rating on (TSE:TLT) stock is a Hold with a C$0.25 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.
Spark’s Take on TLT Stock
According to Spark, TipRanks’ AI Analyst, TLT is a Neutral.
The score is held down primarily by weak financial performance—very large losses versus a small and declining revenue base, ongoing cash burn, and substantial equity erosion. Technicals provide some support with strong recent momentum (price above major moving averages and positive MACD), but elevated RSI suggests the move may be stretched. Valuation remains unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on TLT stock, click here.
More about Theralase Technologies
Theralase Technologies is a Toronto-based clinical-stage pharmaceutical company developing energy-activated small molecules to safely and effectively destroy cancer, bacteria and viruses. Its lead photodynamic compound, Ruvidar (TLD-1433), is being advanced as a potential treatment across multiple infectious and oncologic indications, with a focus on improving outcomes versus current standards of care.
Average Trading Volume: 184,439
Technical Sentiment Signal: Buy
Current Market Cap: C$74.55M
Learn more about TLT stock on TipRanks’ Stock Analysis page.